These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 25926282)
41. Cost-effectiveness analysis of family planning programs in rural Bangladesh: evidence from Matlab. Simmons GB; Balk D; Faiz KK Stud Fam Plann; 1991; 22(2):83-101. PubMed ID: 1907039 [TBL] [Abstract][Full Text] [Related]
42. Efficient Discovery of De-identification Policies Through a Risk-Utility Frontier. Xia W; Heatherly R; Ding X; Li J; Malin B CODASPY; 2013; 2013():59-70. PubMed ID: 25520961 [TBL] [Abstract][Full Text] [Related]
43. Beyond the narco frontier; rethinking an imaginary of the margins. Goodhand J Int J Drug Policy; 2021 Mar; 89():103045. PubMed ID: 33358078 [TBL] [Abstract][Full Text] [Related]
44. The conundrum of cost-effectiveness. Prasad V Cleve Clin J Med; 2012 Sep; 79(9):610-1. PubMed ID: 22949341 [No Abstract] [Full Text] [Related]
45. Simple and less cost but not effective. Lee WL; Chang WH; Wang PH J Chin Med Assoc; 2021 Oct; 84(10):901-902. PubMed ID: 34369463 [No Abstract] [Full Text] [Related]
46. Brain: The New Frontier. Maron JL Clin Ther; 2020 Jul; 42(7):1137-1138. PubMed ID: 32620338 [No Abstract] [Full Text] [Related]
47. "A New Frontier" or "More of the Same"? Lawrie GM Ann Thorac Surg; 2022 Jul; 114(1):349. PubMed ID: 34139185 [No Abstract] [Full Text] [Related]
49. The Frontier Doctor. Atlanta Med Surg J; 1875 Dec; 13(9):571. PubMed ID: 35827373 [No Abstract] [Full Text] [Related]
50. Defining a Willingness-to-transplant Threshold in an Era of Organ Scarcity: Simultaneous Liver-kidney Transplant as a Case Example. Cheng XS; Goldhaber-Fiebert J; Tan JC; Chertow GM; Kim WR; Wall AE Transplantation; 2020 Feb; 104(2):387-394. PubMed ID: 31107820 [TBL] [Abstract][Full Text] [Related]
51. Cost-Utility of Early Breast Cancer Surveillance in Survivors of Thoracic Radiation-Treated Adolescent Hodgkin Lymphoma. Furzer J; Tessier L; Hodgson D; Cotton C; Nathan PC; Gupta S; Pechlivanoglou P J Natl Cancer Inst; 2020 Jan; 112(1):63-70. PubMed ID: 31070751 [TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of multidisciplinary care in mild to moderate chronic kidney disease in the United States: A modeling study. Lin E; Chertow GM; Yan B; Malcolm E; Goldhaber-Fiebert JD PLoS Med; 2018 Mar; 15(3):e1002532. PubMed ID: 29584720 [TBL] [Abstract][Full Text] [Related]
53. Optimal timing of drug sensitivity testing for patients on first-line tuberculosis treatment. Suen SC; Brandeau ML; Goldhaber-Fiebert JD Health Care Manag Sci; 2018 Dec; 21(4):632-646. PubMed ID: 28861650 [TBL] [Abstract][Full Text] [Related]
54. Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview. Dasbach EJ; Elbasha EH Pharmacoeconomics; 2017 Jul; 35(7):673-683. PubMed ID: 28456972 [TBL] [Abstract][Full Text] [Related]
55. The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options. Mühlbacher AC; Sadler A Value Health; 2017 Feb; 20(2):266-272. PubMed ID: 28237207 [TBL] [Abstract][Full Text] [Related]
56. Using propensity scores to estimate the cost-effectiveness of medical therapies. Indurkhya A; Mitra N; Schrag D Stat Med; 2006 May; 25(9):1561-76. PubMed ID: 16158412 [TBL] [Abstract][Full Text] [Related]